

## **Cerulean Pharma Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 07-Mar-2015

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 8

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 16

[Return to Table of Contents](#)

# Cerulean Pharma Inc

## COMPANY OVERVIEW

Company Name	Cerulean Pharma Inc
Parent Company Name	Cerulean Pharma Inc
Website	http://ceruleanrx.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	1
Number of Patents as Owner	26
Number of Patents as Third Party	3
Number of Deals	2
Key Indications	Cancer,Breast tumor,Non-small-cell lung cancer,Ovary tumor,Stomach tumor,Renal tumor,Cardiovascular disease,Advanced solid tumor,Rectal tumor,Small-cell lung cancer
Key Target-based Actions	Topoisomerase I inhibitor,Hypoxia inducible factor-1 alpha inhibitor,Proteasome inhibitor,Topoisomerase II inhibitor,DHFR inhibitor,DNA polymerase inhibitor,Hemagglutinin inhibitor,Hemagglutinin modulator,JAK tyrosine kinase inhibitor,PLK1 gene inhibitor,Thymidylate synthase inhibitor,Transferase inhibitor,VEGF receptor antagonist
Key Technologies	Nanoparticle formulation,Small molecule therapeutic,PEGylated formulation,Intravenous formulation,Nanoparticle formulation injectable,Biological therapeutic,Oligonucleotide,Formulation preservation,Peptide,Controlled release formulation

## COMPANY PROFILE

### SUMMARY

Cerulean Pharma (formerly Tempo Pharmaceuticals Inc) is a biopharmaceutical company specializing in the development of nanoparticle-based therapeutics for oncology, autoimmune and inflammatory diseases, based on its Nanocell technology that was exclusively licensed from the Massachusetts Institute of Technology. In October 2008, the company changed its name to Cerulean Pharma.

### FINANCIAL

In January 2015, the company entered into a loan and security agreement with Hercules Technology Growth Capital for a term loan of up to \$26.0 million and completed a private placement for \$1.0 million of Cerulean common stock with Hercules. Cerulean issued Hercules a warrant to purchase 171,901 shares of Cerulean common stock at an exercise price of \$6.05 per share. At that time, Hercules purchased 135,501 shares of unregistered Cerulean common stock at \$7.38 per share for an aggregate purchase price of \$1.0 million.

In April 2014, Cerulean priced its IPO of 8,500,000 shares of its common stock US \$7.00 per share. Underwriters were granted a 30-day option to purchase an additional 1,275,000 shares. Stock to be listed on the NASDAQ Global Market under the ticker symbol 'CERU'. At that time, the offering was expected to close on April 15, 2014. Later that month, the offering was closed. In May 2014, underwriters for the IPO exercised their over-allotment option and purchased an additional 1,069,715 shares, bringing total number of shares sold to 9,569,715 shares and total gross proceeds to \$67 million.

In December 2011, Cerulean raised \$15 million from a series D financing.

In November 2010, Cerulean raised \$24 million from a series C financing.

In July 2009, Cerulean raised \$10 million from a series B-1 financing.

In January 2008, Tempo raised \$8.1 million from a series B financing.

[Return to Table of Contents](#)



In May 2007, Tempo raised \$12.1 million from a series A financing round.

In December 2006, Tempo raised \$2 million from a seed round.

## COMPANY FINANCIALS

### SHARE INFORMATION

Close Price (USD)	8.12
Change (USD)	0.14 (1.80%)
Previous Close Price (USD)	7.98
Volume	20,553
52-Week High (USD)	8.46
52-Week Low (USD)	3.35
Date	06-Mar-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	20,125,049
Current Market Capitalization	165,629,153
EPS (Date Reported)	-1.19837

[Return to Table of Contents](#)

## STOCK PERFORMANCE



## MAJOR SHAREHOLDERS


Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Fidelity Select Biotechnology Portfolio	Mutual Fund	United States	1,901,400	9.45	0	0	31-Jan-2015
Fidelity Advisor Biotechnology Fund	Mutual Fund	United States	530,000	2.63	0	0	31-Jan-2015
Principal SmallCap Blend Fund	Mutual Fund	United States	100,100	0.5	1,800	0.02	31-Jan-2015
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	28,566	0.14	0	0	31-Jan-2015
Fidelity Spartan Extended Market Index Fund	Mutual Fund	United States	20,034	0.1	0	0	31-Jan-2015
Principal Variable Contract SmallCap Blend Account	Mutual Fund	United States	12,120	0.06	0	0	31-Jan-2015
Fidelity NASDAQ Composite Index Fund	Mutual Fund	United States	4,980	0.02	0	0	31-Jan-2015

[Return to Table of Contents](#)



Guggenheim Investments	Investment Advisor/ Hedge Fund	United States	1,773	0.01	0	0	28-Feb-2015
Wilshire Micro-Cap ETF	Mutual Fund	United States	1,773	0.01	0	0	31-Jan-2015
AXA/Lord Abbett Micro Cap Portfolio	Mutual Fund	United States	1,590	0.01	0	0	31-Jan-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	1,415	0.01	0	0	31-Jan-2015

## FINANCIAL PERFORMANCE



	2011	2012	2013		
<b>Sales (USD M)</b>	0.305	0.625	0.006		
<b>Operating Income (USD M)</b>	-18.878	-21.575	-15.86		
<b>Net Income (USD M)</b>	-18.942	-22.101	-17.143		

[Return to Table of Contents](#)

## Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q3	0	-5.369	-5.558
2014 Q2	0.033	-4.644	-7.403
2014 Q1	0.047	-2.958	-2.914
2013 Q4	0.006	-3.009	-3.48
2013 Q3	0	-2.813	-3.198
2013 Q2	0	-4.587	-4.893
2013 Q1	0	-5.451	-5.572
2012 Q4	0	-5.188	-5.526

## BALANCE SHEET

### Assets (USD M)

	2011	2012	2013		
Cash & Short Term Investments	15.345	16.707	5.488		
Inventories - Total	0	0	0		
Current Assets - Total	15.677	17.064	6.447		
Property, Plant And Equipment - Net	0.611	0.442	0.245		
Other Assets - Total	0.402	0.155	0.135		
Total Assets	16.69	17.661	6.827		

### Liabilities (USD M)

	2011	2012	2013		
Accounts Payable	1.063	0.9	0.914		
Short Term Debt & Current Portion Of Long Term Debt	0.127	2.869	11.958		
Current Liabilities - Total	3.514	6.524	15.146		
Long Term Debt	0	6.258	3.124		
Deferred Taxes	0	0	0		
Other Liabilities	0.822	1.167	1.331		
Total Liabilities	4.336	13.949	19.601		

[Return to Table of Contents](#)



## Stockholders Equity (USD M)

	2011	2012	2013		
Minority Interest	0	0	0		
Preferred Stock	70.751	83.751	81.525		
Common Stock	0.001	0.001	0		
Treasury Stock	0	0	0		
Total Liabilities & Shareholders' Equity	16.69	17.661	6.827		

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-2.16	-2.16	-2.16
31-Dec-2016	-2.36	-2.31	-2.36
31-Dec-2017	-3.31	-3.18	-3.31

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015			-44.91	0
31-Dec-2016			-57.34	0
31-Dec-2017			-75.55	2.14


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	4	1	5
Endocrine disease	2	0	2
Gynecology and obstetrics	2	0	2
Gastrointestinal disease	1	0	1
Respiratory disease	1	0	1
Genitourinary disease	1	0	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Discovery	2
No Development Reported	1

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	0	0	1	0	1
Drug - Development Services	0	0	1	0	1

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	3	6
Genitourinary disease	1	2
Gastrointestinal disease	1	1

[Return to Table of Contents](#)

Gynecology and obstetrics	0	1
Respiratory disease	0	1
Endocrine disease	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	1	3
Phase 1	2	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

### PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	10	1	11
Endocrine disease	12	0	12
Gastrointestinal disease	12	0	12
Genitourinary disease	8	0	8
Growth disorder	1	0	1
Hematological disease	4	0	4
Degeneration	2	0	2
Andrology	2	0	2
Immune disorder	15	1	16
Psychiatric disorder	1	0	1
Musculoskeletal disease	6	0	6
Neoplasm	24	1	25
Ocular disease	2	0	2
Genetic disorder	2	0	2

[Return to Table of Contents](#)



Metabolic disorder	11	0	11
Neurological disease	6	0	6
Nutritional disorder	3	0	3
Respiratory disease	6	2	8
Infectious disease	5	2	7
Inflammatory disease	14	1	15
Otorhinolaryngological disease	1	0	1
Gynecology and obstetrics	8	0	8
Dermatological disease	6	0	6

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### camptothecin nanoparticle (cancer), Cerulean Pharma

<b>Drug Name</b>	camptothecin nanoparticle (cancer), Cerulean Pharma
<b>Key Synonyms</b>	
<b>Originator Company</b>	Calando Pharmaceuticals Inc
<b>Active Companies</b>	Cerulean Pharma Inc
<b>Inactive Companies</b>	Calando Pharmaceuticals Inc
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Small-cell lung cancer, Non-small-cell lung cancer, Breast tumor, Renal tumor, Ovary tumor, Stomach tumor, Rectal tumor
<b>Target-based Actions</b>	Topoisomerase I inhibitor, Hypoxia inducible factor-1 alpha inhibitor
<b>Other Actions</b>	Synergist, Anticancer
<b>Technologies</b>	Nanoparticle formulation injectable, Controlled release formulation, Intravenous formulation, Small molecule therapeutic
<b>Last Change Date</b>	04-Mar-2015

### docetaxel (Cyclodextrin Nanoparticle Technology), Cerulean

<b>Drug Name</b>	docetaxel (Cyclodextrin Nanoparticle Technology), Cerulean
<b>Key Synonyms</b>	
<b>Originator Company</b>	Cerulean Pharma Inc
<b>Active Companies</b>	Cerulean Pharma Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Advanced solid tumor, Cancer
<b>Target-based Actions</b>	
<b>Other Actions</b>	Microtubule inhibitor, Anticancer, Cell cycle inhibitor
<b>Technologies</b>	Nanoparticle formulation injectable, Intravenous formulation, Small molecule therapeutic
<b>Last Change Date</b>	30-Jan-2015

[Return to Table of Contents](#)





### siRNA-containing polymeric nanoparticle technology (cancer), Cerulean

<b>Drug Name</b>	siRNA-containing polymeric nanoparticle technology (cancer), Cerulean
<b>Key Synonyms</b>	
<b>Originator Company</b>	Cerulean Pharma Inc
<b>Active Companies</b>	Cerulean Pharma Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Breast tumor
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anticancer, siRNA agent
<b>Technologies</b>	Oligonucleotide, Nanoparticle formulation, Biological therapeutic
<b>Last Change Date</b>	24-Sep-2014

### CRLX-522

<b>Drug Name</b>	CRLX-522
<b>Key Synonyms</b>	
<b>Originator Company</b>	Cerulean Pharma Inc
<b>Active Companies</b>	Cerulean Pharma Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anticancer
<b>Technologies</b>	Nanoparticle formulation, Small molecule therapeutic
<b>Last Change Date</b>	17-Apr-2014

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

